Patents by Inventor Fabio Bertozzi
Fabio Bertozzi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230212157Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.Type: ApplicationFiled: February 1, 2023Publication date: July 6, 2023Inventors: Tiziano Bandiera, Fabio Bertozzi, Paolo Di Fruscia, Federico Sorana, Emanuela Caci, Loretta Ferrera, Nicoletta Pedemonte, Luis Juan Vicente Galietta
-
Patent number: 11597723Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof. It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.Type: GrantFiled: March 14, 2018Date of Patent: March 7, 2023Assignees: Fondazione Istituto Italiano Di Technologia, Istituto Giannina Gasiini, FondaZione Per La Ricerca Sulla Fibrosi Cristica—OnlusInventors: Tiziano Bandiera, Fabio Bertozzi, Paolo Di Fruscia, Federico Sorana, Emanuela Caci, Loretta Ferrera, Nicoletta Pedemonte, Luis Juan Vicente Galietta
-
Publication number: 20220089584Abstract: The present invention relates to compounds of Formula (Ia) or pharmaceutically acceptable salts, hydrates, solvates, clathrates, polymorphs, stereoisomers thereof. It further discloses a pharmaceutical composition comprising compounds of Formula (Ia) and the use of compounds of Formula (Ib), in particular to modulate CFTR protein or ABC protein activities.Type: ApplicationFiled: January 16, 2020Publication date: March 24, 2022Inventors: Tiziano Bandiera, Fabio Bertozzi, Giorgia Zaetta, Frederico Sorana, Emanuela Caci, Loretta Ferrera, Nicoletta Pedemonte, Luis Juan Vicente Galietta
-
Publication number: 20210292324Abstract: The present invention relates to compounds of Formula (Ia) or pharmaceutically acceptable salts, hydrates, solvates, clathrates, polymorphs, stereoisomers thereof. It further discloses a pharmaceutical composition comprising the compounds of Formula (Ia) and the use of compounds of Formula (Ib), in particular to modulate CFTR protein or ABC protein activities.Type: ApplicationFiled: July 12, 2019Publication date: September 23, 2021Inventors: Tiziano Bandiera, Fabio Bertozzi, Francesca Giacomina, Simone Giovani, Federico Sorana, Emanuela Caci, Loretta Ferrera, Nicoletta Pedemonte, Luis Juan Vicente Galietta
-
Patent number: 10968225Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.Type: GrantFiled: August 14, 2020Date of Patent: April 6, 2021Inventors: Tiziano Bandiera, Fabio Bertozzi, Paolo Di Fruscia, Federico Sorana, Francesco Berti, Alejandra Rodriguez Gimeno, Emanuela Caci, Loretta Ferrera, Nicoletta Pedemonte, Luis Juan Vicente Galietta
-
Patent number: 10865194Abstract: Pharmaceutical compounds are disclosed having a bicyclic-sulphonamide structure of Formula 1: wherein R1 represents an unsubstituted or a substituted heteroaryl ring; R2, R3, R4, and R5 are independently selected from hydrogen, alkyl, hydroxyalkyl, and alkyl-O-alkyl, provided that either R2 and R3, or R4 and R5 are linked or taken together to form a bridge between the carbon atoms to which R2 and R3, or R4 and R5 respectively are directly linked, whereby the N-containing ring in Formula 1 is an azabicyclo moiety. The compounds and compositions including the compounds may be used in therapy as brain-cell-death protectants, for example, in the treatment of chronic neurodegenerative diseases. The compounds are active as inhibitors of N-acylethanolamine-hydrolysing acid amidase (NAAA) and may be used for the therapeutic treatment and prevention of pain and inflammatory disorders and other disorders which benefit from the modulation of fatty acid ethanolamides, particularly palmitoylethanolamide (PEA).Type: GrantFiled: November 3, 2017Date of Patent: December 15, 2020Assignee: FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIAInventors: Fabio Bertozzi, Tiziano Bandiera, Silvia Pontis, Angelo Reggiani, Francesca Giacomina, Paolo Di Fruscia
-
Publication number: 20200369663Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.Type: ApplicationFiled: August 14, 2020Publication date: November 26, 2020Inventors: Tiziano Bandiera, Fabio Bertozzi, Paolo Di Fruscia, Federico Sorana, Francesco Berti, Alejandra Rodriguez Gimeno, Emanuela Caci, Loretta Ferrera, Nicoletta Pedemonte, Luis Juan Vicente Galietta
-
Patent number: 10745407Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.Type: GrantFiled: March 14, 2018Date of Patent: August 18, 2020Assignee: Fondazione Istituto Italiano Di TecnologiaInventors: Tiziano Bandiera, Fabio Bertozzi, Paolo Di Fruscia, Federico Sorana, Francesco Berti, Alejandra Rodriguez Gimeno, Emanuela Caci, Loretta Ferrera, Nicoletta Pedemonte, Luis Juan Vicente Galietta
-
Publication number: 20200131157Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof. It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.Type: ApplicationFiled: March 14, 2018Publication date: April 30, 2020Inventors: Tiziano Bandiera, Fabio Bertozzi, Paolo Di Fruscia, Federico Sorana, Emanuela Caci, Loretta Ferrera, Nicoletta Pedemonte, Luis Juan Vicente Galietta
-
Publication number: 20200002348Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.Type: ApplicationFiled: March 14, 2018Publication date: January 2, 2020Inventors: Tiziano Bandiera, Fabio Bertozzi, Paolo Di Fruscia, Federico Sorana, Francesco Berti, Alejandra Rodriguez Gimeno, Emanuela Caci, Loretta Ferrera, Nicoletta Pedemonte, Luis Juan Vicente Galietta
-
Patent number: 10364242Abstract: Pharmaceutical compositions make up a compound acting as inhibitor of N-acylethanolamine-hydrolyzing acid amidase (NAAA), may be used for the therapeutical treatment and prevention of pain and inflammatory disorders and other disorders which benefit from the modulation of fatty acid ethanolamines, particularly palmitoylethanolamide (PEA). The compound is used in methods of inhibiting NAAA and methods of therapeutical treatment and prevention of pain and inflammation.Type: GrantFiled: November 3, 2017Date of Patent: July 30, 2019Assignee: FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIAInventors: Fabio Bertozzi, Tiziano Bandiera
-
Publication number: 20190135802Abstract: Pharmaceutical compositions make up a compound acting as inhibitor of N-acylethanolamine-hydrolysing acid amidase (NAAA), may be used for the therapeutical treatment and prevention of pain and inflammatory disorders and other disorders which benefit from the modulation of fatty acid ethanolamines, particularly palmitoylethanolamide (PEA). The compound is used in methods of inhibiting NAAA and methods of therapeutical treatment and prevention of pain and inflammation.Type: ApplicationFiled: November 3, 2017Publication date: May 9, 2019Inventors: Fabio BERTOZZI, Tiziano BANDIERA
-
Publication number: 20190135778Abstract: Pharmaceutical compounds have a bicyclic-sulphonamide structure and pharmaceutical compositions including the compounds may be used in therapy as brain-cell-death protectants and may be used, for example, in the treatment of chronic neurodegenerative diseases. The compounds are active as inhibitors of N-acylethanolamine-hydrolysing acid amidase (NAAA) and may be used for the therapeutic treatment and prevention of pain and inflammatory disorders and other disorders which benefit from the modulation of fatty acid ethanolamides, particularly palmitoylethanolamide (PEA).Type: ApplicationFiled: November 3, 2017Publication date: May 9, 2019Inventors: Fabio BERTOZZI, Tiziano BANDIERA, Silvia PONTIS, Angelo REGGIANI, Francesca GIACOMINA, Paolo DI FRUSCIA
-
Patent number: 9908848Abstract: Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.Type: GrantFiled: September 14, 2015Date of Patent: March 6, 2018Assignees: The Regents of the University of California, Fondazione Istituto Italiano di Tecnologia, Universita Degli Studi di Urbino “Carlo Bo”, Universita Degli Studi di ParmaInventors: Daniele Piomelli, Marco Mor, Giorgio Tarzia, Fabio Bertozzi, Andrea Nuzzi, Annalisa Fiasella, Tiziano Bandiera, Angelo Mario Reggiani
-
Patent number: 9828338Abstract: Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.Type: GrantFiled: September 14, 2015Date of Patent: November 28, 2017Assignees: The Regents of the University of California, Fondazione Istituto Italiano di Technologia, Universita Degli Studi di Urbino “Carlo Bo”, Universita Degli Studi di ParmaInventors: Daniele Piomelli, Tiziano Bandiera, Fabio Bertozzi, Andrea Nuzzi, Annalisa Fiasella, Stefano Ponzano, Chiara Pagliuca, Angelo Mario Reggiani, Marco Mor, Giorgio Tarzia
-
Publication number: 20160235707Abstract: The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.Type: ApplicationFiled: April 25, 2016Publication date: August 18, 2016Inventors: Daniele Piomelli, Tiziano Bandiera, Marco Mor, Giorgio Tarzia, Fabio Bertozzi, Stefano Ponzano
-
Patent number: 9353075Abstract: The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.Type: GrantFiled: November 21, 2012Date of Patent: May 31, 2016Assignees: The Regents of the University of California, Fondazione Istituto Italiano Di Technologia, Universita Degli Studi Di Parma, Universita Degli Studi Di Urbino “Carlo Bo”Inventors: Daniele Piomelli, Tiziano Bandiera, Marco Mor, Giorgio Tarzia, Fabio Bertozzi, Stefano Ponzano
-
Publication number: 20160068483Abstract: Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.Type: ApplicationFiled: September 14, 2015Publication date: March 10, 2016Inventors: Daniele Piomelli, Marco Mor, Giorgio Tarzia, Fabio Bertozzi, Andrea Nuzzi, Annalisa Fiasella, Tiziano Bandiera, Angelo Mario Reggiani
-
Publication number: 20160068482Abstract: Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.Type: ApplicationFiled: September 14, 2015Publication date: March 10, 2016Inventors: Daniele Piomelli, Tiziano Bandiera, Fabio Bertozzi, Andrea Nuzzi, Annalisa Fiasella, Stefano Ponzano, Chiara Pagliuca, Angelo Mario Reggiani
-
Publication number: 20050136444Abstract: The invention described below relates to the discovery of the neuropeptide FF receptor subtype that mediates acute nociception and chronic neuropathic pain, compounds that selectively interact with this receptor subtype and methods for treating acute pain and chronic neuropathic pain.Type: ApplicationFiled: September 24, 2004Publication date: June 23, 2005Inventors: Audra Scully, Robert Davis, Kimberly Vanover, Luis Gardell, Jelveh Lameh, Nicholas Kelly, Fabio Bertozzi